RELEASE $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT South San Francisco, Calif., August 7, 2025 -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported second quarter 2025 financial results and recent portfolio and business updates. As of ...

Funko Reports Second Quarter 2025 Financial Results --Company Provides Comments on H2 Outlook-- EVERETT, Wash. August 7, 2025 -- Funko, Inc. (Nasdaq: FNKO), a leading pop culture lifestyle brand, today reported its consolidated financial results for the second quarter ended June 30, 2025. Second Quarter Financial Results Summary: 2025 vs 2024 "As expected, our 2025 second quarter performance was impacted by a dynamic and uncertain tariff environment," said Mike Lunsford, Interim Chief Executive Officer of F ...

Exhibit 99.1 Rackspace Technology Reports Second Quarter 2025 Results SAN ANTONIO, August 7, 2025 – Rackspace Technology, Inc. (Nasdaq: RXT), a leading end-to-end, hybrid cloud and AI solutions company, today announced results for its second quarter ended June 30, 2025. Amar Maletira, Chief Executive Officer, stated, "I am pleased with our second quarter results. Revenue and operating profit exceeded the midpoint of guidance and EPS was within our guided range." Mr. Maletira added, "Go‑to‑market execution a ...

COMPANY CONTACTS Briony Quinn Chief Financial Officer (240) 744-1196 Dori Kesten Capital Markets (617) 835-8366 DIAMONDROCK HOSPITALITY COMPANY REPORTS SECOND QUARTER 2025 RESULTS "RevPAR in the second quarter was in line with our expectations, with demand down modestly and rates up compared to the same time last year. Out-of-room spend accelerated from levels experienced in the first quarter, and that trend has continued into the third quarter. Excluding a larger than anticipated property tax increase in C ...

Exhibit 99.1 Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 Cambridge, Mass. – August 7, 2025 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small mo ...

Westrock Coffee Company Reports Second Quarter 2025 Results and Reaffirms 2025 and 2026 Outlook Exhibit 99.1 Little Rock, Ark., August 7, 2025 (GLOBE NEWSWIRE) – Westrock Coffee Company (Nasdaq: WEST) ("Westrock Coffee" or the "Company") today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights 1 Commenting on our results, Scott T. Ford, CEO and Co-founder stated, "We are pleased to report record quarterly segment performance as we celebrate the successful launch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31565 Flagstar Financial, Inc. (Exact name of registrant as specified in its charter) | Delaware | | 06-1377322 | | --- | --- | --- | | (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-36393 Paycom Software, Inc. (Exact name of registrant as specified in its charter) Delaware FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31565 Flagstar Financial, Inc. (Exact name of registrant as specified in its charter) | Delaware | | 06-1377322 | | --- | --- | --- | | (State or other jurisdicti ...

Exhibit 99.1 Kura Oncology Reports Second Quarter 2025 Financial Results – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through ...